Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: A pilot study

Journal of Viral Hepatitis

Volumn 11, Issue 3, 2004, Pages 225-235

  Kumagai, N ^a   Takahashi, N ^b   Kinoshita, M ^b   Tsunematsu, S ^a   Tsuchimoto, K ^a   Saito, H ^c   Ishii, H ^c  

^a KITASATO INSTITUTE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Amino acid sequence motifs; Direct sequencing; Genotype 1b; Hepatitis C virus; Nucleoside analogue; RNA dependent RNA polymerase

Indexed keywords

ALPHA2B INTERFERON; GLUTAMIC ACID; ISOLEUCINE; LYSINE; NONSTRUCTURAL PROTEIN 5B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG; VALINE; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

AGED; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PILOT PROJECTS; POLYMORPHISM, GENETIC; RIBAVIRIN; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL NONSTRUCTURAL PROTEINS;

EID: 2442659173     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00501.x     Document Type: Article

References (38)

1. Pol S, Nalpas B, Bourliere M et al. Combination of ribavirin and interferon-alpha surpasses high doses of interferon-alpha alone in patients with genotype-1b-related chronic - hepatitis C. Hepatology 2000; 31: 1338-1344.
2. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 211-218.
3. Saracco G, Ciancio A, Olivero A et al. randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34: 133-138.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
5. Manns MP, McHuchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
6. Crotty S, Maag D, Arnold J et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375-1379.
7. Lanford RE, Guerra B, Lee H et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77: 1092-1104.
8. Bekkering FC, Brouwer JT, Leroux-Roels G, Vlierberghe HV, Elewant A, Schlm W. Ultra rapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960-964.
9. Zeuzem S, Lee JH, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 1998; 27: 1149-1156.
10. Svensson JO, Bruchfeld A, Scvarcz R, Stahle L. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. Ther Drug Monit 2000; 22: 213-218.
11. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 (Suppl. 1): 17-24.
12. Matteucci MD, Caruthers MH. Synthesis of deoxyoligonucleotides on a polymer support. Biotechnology 1981; 24: 92-98.
13. Kato N, Hijikata M, Ootsuyama Y et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-9528.
14. Sambrook J, Fitsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. NY: CSH Laboratory Press, 1990; 7-8.
15. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb-Viewer: an environment for comparative protein modeling. Electrophoresis 1997; 18: 2714-2723.
16. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-982.
17. Buti M, Sanchez-Avila F, Lurie Y et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-936.
18. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med 1998; 339: 1485-1492.
19. Ferenci, P, Brunner H, Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
20. Asahina Y, Izumi N, Uchihara M et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34: 377-384.
21. Lau JYN, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-1009.
22. Tam RC, Pai B, Bard J et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30: 376-382.
23. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276: 46094-46098.
24. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 2000; 7: 167-174.
25. Bressanelli S, Tomei L, Roussel A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999; 96: 13032-13039.
26. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937-943.
27. Qin W, Yamashita T, Shirota Y, Lin Y, Wei W, Marakami S. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 2001; 33: 728-737.
28. Ago H, Adachi T, Yoshida A et al. Crystal Structure of the RNA-Directed RNA Polymerase of Hepatitis C Virus. Structure (London) 1999; 7: 1417-1426.
29. O'Farrell D, Trowbridge R, Rowlands D, Jager J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol 2003; 326: 1025-1035.
30. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 2003; 100: 7289-7294.
31. Lewis DA, Bebenek K, Beard WA Wilson SH, Kunkel TA. Uniquely altered DNA replication fidelity conferred by an amino acid change in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 1999; 274: 32924-32930.
32. Gutierrez-Rivas M, Menendez-Arias L. A mutation in the primer grip region of HIV-1 reverse transcriptase that confers reduced fidelity of DNA synthesis. Nucleic Acids Res. 2001; 29: 4963-4972.
33. Huang H, Chopra R, Verdine, Harrison SC. Structure of a covalently trapped catalytic complex of HTV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-1675.
34. Ishido S, Fujita T, Hotta H. Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. Biochem Biophys Res Commun 1998; 244: 35-40.
35. Piccininni S, Varaklioti A, Nardelli M, Dave B, Raney KD, McCarthy EG. Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. J Biol Chem 2002; 277: 45670-45679.
36. Shirota Y, Luo H, Qin W et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRp) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002; 277: 11149-11155.
37. Dimitrova M, Imbert I, Kieny MP, Schuster C. Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol 2003; 77: 5401-5414.
38. Young KC, Lindsay KL, Lee KJ et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003; 38: 869-878.